Skip to main content
Premium Trial:

Request an Annual Quote

iCubate Receives CE Mark for Dx Platform, Bloodstream Infection Assay

NEW YORK (GenomeWeb) – iCubate announced yesterday that it has received CE mark for its first clinical assay, the iC-GPC assay and its platform, the iC-System, used for the rapid diagnosis of pathogenic bacteria associated with bloodstream infection. The CE mark provides an entry for iCubate to begin market integration into the European Union.

The iC-GPC assay leverages iCubate's amplicon rescued multiplex PCR (ARM-PCR) technology, which detects multiple pathogens simultaneously and was developed by company founder and CSO Jian Han. The end result is an improved turnaround time for pathogen identification and detection of antimicrobial resistance markers.  

The iC-GPC assay is a multiplexed, in vitro diagnostic test for the detection and identification of possible pathogenic gram-positive bacteria. The panel identifies bacteria frequently linked to BSI, while providing crucial information specific to resistance markers of interest in patient treatment and management.

"Integrating the iC-System and iC-GPC assay into the European market is a major step toward our overall goal of improved patient treatment through personalized diagnostics," Han said in a statement.

Testing with the iC-GPC assay uses a positive blood culture, with results available in a few hours, rather than with usual microbiological methods that require two to four days to generate results. The system identifies about 90 percent of organisms isolated from a blood culture, while identifying key resistance markers specific to the detection of vancomycin-resistant Enterococcus and methicillin resistant Staphylococcus.

Earlier this month, iCubate's iC-GPC BSI assay received 510(k) clearance from the US Food and Drug Administration.  

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.